Quanterix: Strong Q3 Performance and Growth Prospects Justify Buy Rating
Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Quanterix (QTRX – Research Report), with a price target of ...
bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results
(NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of expectations for ...